Your browser doesn't support javascript.
loading
The Critical Blood-Sparing Effect of Tranexamic Acid (TXA) in Liposuction: A Systematic Review and Meta-Analysis.
Reinhardt, Myrna Eliann; Mutyala, Sudeep; Gerald, Mykal; Zhao, Huaqing; Nova, Vitalina; Araya Cambronero, Sthefano; Patel, Sameer; Baltodano, Pablo A.
Affiliation
  • Reinhardt ME; Albany Medical College, Albany, NY, USA.
  • Mutyala S; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Gerald M; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Zhao H; Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Nova V; Temple University, Charles Library, Philadelphia, PA, USA.
  • Araya Cambronero S; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Patel S; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Baltodano PA; Miami Beauty Specialists, Miami, FL, USA.
JPRAS Open ; 40: 48-58, 2024 Jun.
Article de En | MEDLINE | ID: mdl-38425698
ABSTRACT

Introduction:

Tranexamic acid (TXA) has been used to improve bleeding outcomes in many surgical procedures. However, its blood-sparing effect in liposuction is not well established.

Methods:

A systematic literature search was performed using PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Cochrane Central, ClinicalTrials.gov, and WorldWideScience.org databases from their inception to October 8, 2021, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The authors focused on 3 main topics 1) TXA, 2) liposuction, and 3) complications. We included articles evaluating the potential blood-sparing effects of TXA in liposuction. Studies were excluded if they were systematic review articles or protocol papers, animal studies, conference abstracts, survey studies, or non-English publications.

Results:

A total of 711 articles were identified, with 1 retrospective and 4 prospective (3 randomized) studies meeting our inclusion criteria. TXA was used in various forms administered intravenously either on induction or after the procedure, mixed into the tumescent solution, or infiltrated into the liposuction sites after lipoaspiration. A significantly smaller reduction in hematocrit was noted in the TXA group compared with that in the non-TXA group (p<0.001) despite a significantly greater amount of lipoaspirate removed in the TXA group (p<0.001). Patients in non-TXA cohorts experienced adverse effects (such as seroma and need for transfusion) that were not seen in TXA cohorts.

Conclusion:

TXA use in patients undergoing liposuction seems to be associated with a beneficial blood-sparing effect, which may enhance safety in this population. Future studies should aim to determine the optimal route and dosing for TXA in liposuction. Evidence Based Medicine Level IV.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: JPRAS Open Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Pays-Bas

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: JPRAS Open Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Pays-Bas